Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nemorubicin

Next Previous
X
Search
Drug Profile

Nemorubicin

Alternative Names: FCE 23762; Methoxymorpholinyl doxorubicin; PNU 152243; PNU-152243A

Latest Information Update: 21 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action DNA intercalators; DNA topoisomerase I inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Liver cancer; Solid tumours

Most Recent Events

  • 22 Apr 2009 Preclinical cardiotoxicity data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 09 Nov 2007 Data presented at the 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2007) added to the adverse events and Cancer therapeutic trials sections
  • 19 Apr 2007 Phase-II clinical trials in liver cancer in France, Germany, Italy and United Kingdom (Intra-arterial) (EudraCT2005-000731-26)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top